Cargando…
New Immunosuppressive Therapies in Uveitis Treatment
Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581271/ https://www.ncbi.nlm.nih.gov/pubmed/26270662 http://dx.doi.org/10.3390/ijms160818778 |
_version_ | 1782391532648660992 |
---|---|
author | Mérida, Salvador Palacios, Elena Navea, Amparo Bosch-Morell, Francisco |
author_facet | Mérida, Salvador Palacios, Elena Navea, Amparo Bosch-Morell, Francisco |
author_sort | Mérida, Salvador |
collection | PubMed |
description | Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines. |
format | Online Article Text |
id | pubmed-4581271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45812712015-09-28 New Immunosuppressive Therapies in Uveitis Treatment Mérida, Salvador Palacios, Elena Navea, Amparo Bosch-Morell, Francisco Int J Mol Sci Review Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines. MDPI 2015-08-11 /pmc/articles/PMC4581271/ /pubmed/26270662 http://dx.doi.org/10.3390/ijms160818778 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mérida, Salvador Palacios, Elena Navea, Amparo Bosch-Morell, Francisco New Immunosuppressive Therapies in Uveitis Treatment |
title | New Immunosuppressive Therapies in Uveitis Treatment |
title_full | New Immunosuppressive Therapies in Uveitis Treatment |
title_fullStr | New Immunosuppressive Therapies in Uveitis Treatment |
title_full_unstemmed | New Immunosuppressive Therapies in Uveitis Treatment |
title_short | New Immunosuppressive Therapies in Uveitis Treatment |
title_sort | new immunosuppressive therapies in uveitis treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581271/ https://www.ncbi.nlm.nih.gov/pubmed/26270662 http://dx.doi.org/10.3390/ijms160818778 |
work_keys_str_mv | AT meridasalvador newimmunosuppressivetherapiesinuveitistreatment AT palacioselena newimmunosuppressivetherapiesinuveitistreatment AT naveaamparo newimmunosuppressivetherapiesinuveitistreatment AT boschmorellfrancisco newimmunosuppressivetherapiesinuveitistreatment |